Contact Molecules for Homologous Proteins
[Summary Bars]	[Full Bars]	Site Table[90 %]	[Back to Search Page]	[Back to HOMCOS]
[Sites by Variants]	[SupCon3D]	[help]	seq_id(%): [0] [30] [40] [50] [60] [70] [80] [90] [95] [100]	[show] [download] [help]

PID	QueryLength	Homolgous Sequence in PDB	UniProt Query	TITLE
2691701	207	27	P51149(RAB7A_HUMAN)	RecName: Full=Ras-related protein Rab-7a ; EC=3.6.5.2 ;
QUERYSEQ	MTSRKKVLLKVIILGDSGVGKTSLMNQYVNKKFSNQYKATIGADFLTKEVMVDDRLVTMQIWDTAGQERFQSLGVAFYRGADCCVLVFDVTAPNTFKTLDSWRDEFLIQASPRDPENFPFVVLGNKIDLENRQVATKRAQAWCYSKNNIP YFETSAKEAINVEQAFQTIARNALKQETEVELYNEFPEPIKLDKNDRAKASAESCSC

  [n]:site number of query sequence.  [a]:amino acid of query sequence.  [s]:predicted secondary structure.
  [e]:predicted exposed/buried.  [acc]:predicted relative accesssibility(%).  [pdb]:PDB code of homologous structure.
  [contact_mols]:predicted binding molecules  [observed aa]:Observed amino acids among homologous sequences.  [feature table]:UniProt Feature Table
  [variant]:UniProt Human Variant.

n	a	s	e	acc	pdb	contact_mols	observed aa	feature table	variant
1	M	-	-	-	-		M	INIT_MET /note="Removed" INIT_MET /note="Removed" DISORDER predicted by DISOPRED
2	T	-	-	-	-		STANDLGPV	MOD_RES /note="N-acetylthreonine" MOD_RES /note="N-acetylthreonine" DISORDER predicted by DISOPRED
3	S		e	142.2	1yhn_A	hetero RILP_HUMAN	SPNGKTAEDIQFLY	DISORDER predicted by DISOPRED
4	R		e	41.9	1yhn_A		RKQENGSTDHIYP
5	K		e	62.3	1yhn_A		KRSQYENADFHLPT
6	K		e	66.0	1vg0_B		KEDSRNIQVPAH
7	V		e	54.0	1vg8_D		VLIAKPTDGHSYENRFMCQ
8	L	E	e	46.1	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN	LVEIAFRDMQKNSTY	MUTAGEN /note="L->A: Abolishes interaction with RILP and reduces its localization to late endosomal/lysosomal compartments." MUTAGEN /note="L->A: Abolishes interaction with RILP and reduces its localization to late endosomal/lysosomal compartments."
9	L	E	b	0.0	1vg8_D		FLIVMYARCHS
10	K	E	b	16.5	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN	KREHNQST	MUTAGEN /note="K->A: Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments." MUTAGEN /note="K->A: Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments."
11	V	E	b	0.0	1vg8_D		VILCFAMTY
12	I	E	b	0.0	1vg8_D		VLIATGMCS
13	I	E	b	1.2	1vg8_D		LVIMFTACS
14	L	E	b	0.0	1vg8_D		VLIAMCFNRT
15	G		b	0.0	1vg8_D		G	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
16	D		e	20.4	1vg8_D	hetero PDZD8_HUMAN compound GTP GNP GDP	DLAERNSPGHQYKM	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
17	S	T	e	36.7	1vg8_D	hetero RAE1_RAT compound GTP GNP GDP	SGPADRQVYLNTCEIKM	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
18	G	T	e	41.7	1vg8_D	compound GTP GNP GDP	GANSDECKQRTFHLMY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
19	V	S	b	0.0	1vg8_D	compound GTP GNP GDP	VASTCHI	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
20	G	S	b	14.3	1vg8_D	compound GTP GNP GDP	GA	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
21	K	H	b	5.7	1vg8_D	compound GTP GNP GDP metal MG	KI	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
22	T	H	e	26.6	1vg8_D	compound GTP GNP GDP metal MG	TSGKL	MUTAGEN /note="T->N: Abolishes localization on late endosomes, lysosomes and phagosomes and reduces phagosomal fusions. Abolishes association of RILP with the phagosomes. No loss of interaction with CLN5. No loss of interaction with PRPH. Reduced interaction with VPS13A. Inhibits SARS-CoV-2 infection." ECO:0000269|PubMed:22431521, ECO:0000269|PubMed:23179371, ECO:0000269|PubMed:30709847, ECO:0000269|PubMed:34159616" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MUTAGEN /note="T->N: Abolishes localization on late endosomes, lysosomes and phagosomes and reduces phagosomal fusions. Abolishes association of RILP with the phagosomes. No loss of interaction with CLN5. No loss of interaction with PRPH. Reduced interaction with VPS13A. Inhibits SARS-CoV-2 infection." ECO:0000269|PubMed:22431521, ECO:0000269|PubMed:23179371, ECO:0000269|PubMed:30709847, ECO:0000269|PubMed:34159616" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
23	S	H	e	27.3	1vg8_D	compound GTP GNP GDP	SATCNQEFKRV
24	L	H	b	1.1	1vg8_D		LIFMVT
25	M	H	b	5.3	1vg8_D		LVITAMCFRW
26	N	H	e	21.8	1vg8_D		NILVHKESQRYFMTADGC
27	Q	H	b	11.2	1vg8_D		RQSAVKLTCEINFHMY
28	Y	H	b	2.2	1vg8_D		FLYIHADRSTVW
29	V	H	b	18.7	1vg8_D		TLVAICSMGKRQDFHN
30	N	H	e	46.7	1vg8_D		TDGKEQSNRHYLACFM
31	K	S	e	67.9	1vg8_D		GNKDRESTLQAHV
32	K		e	56.1	1vg8_D		ERKQTSAHDIGNPVCLMY		K->E:(17.0 %):LB/B - dbSNP:rs1154975
33	F		e	34.4	1vg8_D	compound GTP GNP GDP	FYVIADGLTEKPRSW
34	S		e	50.0	1vg8_D	compound GTP GNP GDP	SPVEADINQTGLKRCFHMY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
35	N	S	e	77.0	1vg8_D	compound GTP GNP GDP	EDKSTGPNIALMQVHFRY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
36	Q	S	e	79.1	1vg8_D	compound GTP	EDQKVGNSTAHRIPFLMY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
37	Y		e	59.6	1vg8_D	compound GTP GNP	YHTSEFVILPQCMAKRW	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region"
38	K		e	61.8	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN compound GNP GTP	EKDIVAQTLSGPRHNFMY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region"
39	A		b	11.6	1vg8_D	compound GTP GNP	PASGLTQCEHKMNRIVWY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region"
40	T		e	21.4	1vg8_D	compound GTP GNP metal MG	TGSNEPIVAKLQW	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MOTIF /note="Effector region"
41	I		e	57.3	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN OSBL1_MOUSE RUBIC_HUMAN	IVLTAENQSDFGHKY	MOTIF /note="Effector region" MOTIF /note="Effector region"
42	G	S	b	17.9	1vg8_D	hetero RAE1_RAT PDZD8_HUMAN OSBL1_MOUSE RUBIC_HUMAN	GFTEAPSLQRDHIKVY	MOTIF /note="Effector region" MOTIF /note="Effector region"
43	A	E	e	22.3	1vg8_D	hetero RAE1_RAT RILP_HUMAN PDZD8_HUMAN OSBL1_MOUSE RUBIC_HUMAN	VEAIRDFGLQCNSPKT	MOTIF /note="Effector region" MOTIF /note="Effector region"
44	D	E	e	68.5	1vg8_D	hetero RAE1_RAT RILP_HUMAN PDZD8_HUMAN OSBL1_MOUSE RUBIC_HUMAN	DNETARSHIKLYCGV	MOTIF /note="Effector region" MOTIF /note="Effector region"
45	F	E	e	37.3	1vg8_D	hetero RAE1_RAT RILP_HUMAN PDZD8_HUMAN	FYVILSTMQRACDEGHKNP	MOTIF /note="Effector region" MOTIF /note="Effector region"
46	L	E	e	32.6	1vg8_D		YLVKGAFHIRDENSQTCMP
47	T	E	e	42.2	1vg8_D	hetero RILP_HUMAN	TSRVAEIKNLPYDMCFHQW
48	K	E	e	20.3	1vg8_D		KRQAELTPSVGHIYDFNW
49	E	E	e	53.3	1vg8_D		ETQSHKDNVAIRLPFGMY
50	V	E	b	16.7	1vg8_D		VILMFCYAESTDGNW
51	M	E	e	52.7	1vg8_D		TEVMQSHILNYADFPRCGK
52	V	S	b	4.0	1vg8_D		VILTPYAGKMRCEFNQSW
53	D	S	e	67.3	1vg8_D		DENGKRSTPQAFHL
54	D	S	e	93.2	1vg8_D		GDNESKHACFILQRTVY
55	R		e	49.0	1vg8_D		KREQTGADNSHIVLMP
56	L	E	e	59.0	1vg8_D		TLKPERSVQDGIANCFHMY
57	V	E	b	1.3	1vg8_D		VILYCFAMHTEKPS
58	T	E	e	21.4	1vg8_D	hetero RILP_HUMAN	KTLSRNPEHVADGIMQCFY
59	M	E	b	0.0	1vg8_D		LFIVAMTCEY
60	Q	E	b	14.3	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN	QEDHNGKRLAMSTFIV
61	I	E	b	0.0	1vg8_D		ILVFMACT
62	W	E	b	11.2	1vg8_D	hetero RAE1_RAT RILP_HUMAN PDZD8_HUMAN RUBIC_HUMAN	WLFIYVQRMTCH
63	D	E	b	6.8	1vg8_D	hetero RAE1_RAT compound GTP metal MG	DEAGN	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
64	T	E	b	3.9	1vg8_D	compound GNP GTP metal MG	TIVELSAFCGMNPY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
65	A		b	0.9	1vg8_D	hetero RAE1_RAT compound GTP GNP	AGPSCENRDFHKQTVW	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
66	G	S	b	15.5	1vg8_D	hetero PDZD8_HUMAN compound GTP GNP	GSDEAKPQ	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
67	Q	S	e	20.9	1vg8_D	hetero RAE1_RAT OSBL1_MOUSE	QHSLDGKPTAEINCMRW	MUTAGEN /note="Q->L: Does not abolish localization on late endosomes, lysosomes and phagosomes and does not reduce phagosomal fusions. No loss of interaction with CLN5 and VPS13A. Increases interaction with PRPH. Inhibits SARS-CoV- 2 infection." ECO:0000269|PubMed:22431521, ECO:0000269|PubMed:23179371, ECO:0000269|PubMed:30709847, ECO:0000269|PubMed:34159616" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" MUTAGEN /note="Q->L: Does not abolish localization on late endosomes, lysosomes and phagosomes and does not reduce phagosomal fusions. No loss of interaction with CLN5 and VPS13A. Increases interaction with PRPH. Inhibits SARS-CoV- 2 infection." ECO:0000269|PubMed:22431521, ECO:0000269|PubMed:23179371, ECO:0000269|PubMed:30709847, ECO:0000269|PubMed:34159616" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
68	E	G	e	81.4	1vg8_D	hetero PDZD8_HUMAN compound GTP	EDPAQRSGHKNCFILTVY
69	R	G	e	73.9	1vg8_D	hetero RAE1_RAT OSBL1_MOUSE PDZD8_HUMAN	REKDASHQFGILTYCNPVW
70	F	G	e	27.3	1vg8_D	hetero RAE1_RAT RILP_HUMAN PDZD8_HUMAN OSBL1_MOUSE	FYLVAIGCHKDEMNQW
71	Q	S	e	37.8	1vg8_D	hetero RAE1_RAT PDZD8_HUMAN OSBL1_HUMAN metal K precipitant	REQSDKGNTHLAPCVY
72	S		e	33.6	1vg8_D	hetero RAE1_RAT RILP_HUMAN RUBIC_HUMAN PDZD8_HUMAN	SARTEGKNQPCDIVFHLW	MOD_RES /note="Phosphoserine" ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" MOD_RES /note="Phosphoserine" ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
73	L	S	e	99.4	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN OSBL1_MOUSE RUBIC_HUMAN	LMIVTCFAEGHKNPQRSWY
74	G		e	60.7	1vg8_D	hetero RAE1_RAT RUBIC_HUMAN PDZD8_HUMAN	RGTWAPNDILSQVCEFHK
75	V		e	24.0	1vg8_D	hetero RAE1_RAT PDZD8_HUMAN RUBIC_HUMAN	PDSRIEAKVTLQHNCFGMY
76	A	G	e	48.2	1vg8_D	hetero RAE1_RAT RILP_HUMAN RUBIC_HUMAN PDZD8_HUMAN	ASLHQREKMITVGCDFNPW
77	F	G	b	14.4	1vg8_D	hetero RAE1_RAT RILP_HUMAN PDZD8_HUMAN OSBL1_MOUSE RUBIC_HUMAN	YFSRCGILAVWDEHNQ
78	Y	G	b	5.7	1vg8_D	hetero PDZD8_HUMAN	YIMFLSCATGWDHV
79	R	T	e	58.1	1vg8_D	hetero RAE1_RAT RILP_HUMAN RUBIC_HUMAN PDZD8_HUMAN	RKEPSIQTAGNHVLMY
80	G	T	e	69.0	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN	GDNQSWTAKRVEHLCFIMY
81	A		b	4.5	1vg8_D	hetero PDZD8_HUMAN	ATGSVCIFLPQR
82	D		b	7.4	1vg8_D	hetero RILP_HUMAN PDZD8_HUMAN	DNHQEVSALMIKRTY
83	C	E	b	0.0	1vg8_D		GAVCILRFHMTY
84	C	E	b	0.0	1vg8_D		VFAIYCLHGT
85	V	E	b	0.0	1vg8_D		LIVMCFGAT
86	L	E	b	0.0	1vg8_D		LIVFYCMAGHN
87	V	E	b	0.7	1vg8_D		VCMILATFGSY
88	F	E	b	0.0	1vg8_D		YFVIHLQ
89	D	E	b	8.0	1vg8_D		DSANEGIV
90	V	T	b	0.0	1vg8_D		IVLSAGCMNPTY
91	T	T	b	19.5	1vg8_D		TDSANVEHICGQKLM
92	A		e	25.0	1vg8_D		SDNRAKETCQVGHILM
93	P	H	e	22.5	1vg8_D		RPEKQTAGLSHMVYCDFIN
94	N	H	e	75.2	1vg8_D	hetero OSBL1_MOUSE	EDSKQANGRITVHLPW
95	T	H	b	10.4	1vg8_D		STRADNEGHKMP
96	F	H	b	6.7	1vg8_D	hetero OSBL1_MOUSE	FLYIRVESTACKMQ
97	K	H	e	67.0	1vg8_D	hetero OSBL1_MOUSE	EDQKNLSARTHIGMPVY
98	T	T	e	26.0	1vg8_D	hetero OSBL1_MOUSE PDZD8_HUMAN precipitant	NSEAKRHDLVPTGIQYCFM
99	L	H	b	0.0	1vg8_D		VLIAMCSTDFHK
100	D	H	e	35.2	1vg8_D		KEDSQAPRTNGHILYMV
101	S	H	e	63.3	1vg8_D	hetero OSBL1_HUMAN RUBIC_HUMAN PDZD8_HUMAN precipitant	KSNERTAQIDHLGPFMVY
102	W	H	b	8.0	1vg8_D	hetero OSBL1_HUMAN PDZD8_HUMAN precipitant	WLAFYIEKSVCGMQ
103	R	H	b	7.1	1vg8_D	hetero OSBL1_HUMAN	RLIKYHVEAMSFPQTWDGN
104	D	H	e	46.3	1vg8_D	hetero OSBL1_HUMAN RUBIC_HUMAN	EDKQPNSRATGIHLVFMY
105	E	H	e	31.2	1vg8_D	hetero OSBL1_HUMAN RUBIC_HUMAN PDZD8_HUMAN precipitant	EQDKNTLRAPSCGHIMV
106	F	H	b	0.0	1vg8_D	hetero PDZD8_HUMAN	LIFVAYEMWHKSTCDGNPQR
107	L	H	b	15.7	1vg8_D	hetero OSBL1_HUMAN	LIRVKQADEHFSCMNTYGPW
108	I	H	e	67.3	1vg8_D	hetero RAE1_RAT OSBL1_HUMAN RUBIC_HUMAN	LRIKASVQDETNPGHYCFM
109	Q	H	e	30.1	1vg8_D	hetero RUBIC_HUMAN PDZD8_HUMAN	HQKELRYNSTVIMADFGPCW
110	A	H	b	8.9	1vg8_D		ALVRSTCDFGIKENHPQYW
111	S		e	68.8	1vg8_D	hetero RAE1_RAT OSBL1_HUMAN RUBIC_HUMAN	RSAGKDNTELHCPVFIQYM
112	P		b	17.8	1vg8_D	hetero OSBL1_HUMAN	PVASGETHKLDINQRCFYMW
113	R	S	e	48.2	1vg8_D	hetero OSBL1_HUMAN RAE1_RAT	RKELSAGHDNPQYFITVCM
114	D	S	e	43.2	1vg8_D		DGENLVASTQRCHIPFKYM
115	P	G	e	38.0	1vg8_D	hetero OSBL1_HUMAN	PLAKSGTNCDEIHQRVMFWY
116	E	G	e	51.8	1vg8_D	hetero OSBL1_HUMAN	EDKSAQPRTVGHLNIYCFM
117	N	G	e	59.4	1vg8_D		NGDSEKRTAHPLQCIVY
118	F	S	b	3.3	1vg8_D		VILAFTMYCSEGQ
119	P		b	14.0	1vg8_D		PVIATKLNQSCEGHMR
120	F	E	b	1.4	1vg8_D		IVLFMKARTYCGNSW
121	V	E	b	0.0	1vg8_D		VILMATCFGY
122	V	E	b	0.7	1vg8_D		LVIMAG
123	L	E	b	1.1	1vg8_D		VLIACFTM
124	G	E	b	0.0	1vg8_D		GARIQFPSV
125	N	E	b	2.4	1vg8_D	compound GTP GNP GDP	NTCLDHS	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
126	K		e	28.8	1vg8_D	compound GTP GNP GDP	KQRHNY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
127	I	T	e	27.5	1vg8_D		CSIAVLQTKMRDFGNY	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
128	D	T	e	23.5	1vg8_D	compound GTP GNP GDP	DASEHQT	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
129	L	S	e	44.4	1vg8_D	compound GTP GNP GDP	LMIVKARCDEFHPQST		L->F:(1.0 %):LP/P Charcot-Marie-Tooth disease, axonal, 2B (CMT2B) dbSNP:rs1219090 [MIM:600882]
130	E	S	e	96.0	1vg8_D		ERDSAKPQTGHLNVCIMY
131	N		e	83.0	1vg8_D		DNSEHKGTAQRFILMPVY
132	R		e	34.4	1vg8_D		REKDQSGYAHLNTVIMP
133	Q		e	63.8	1vg8_D		QREKVADLPSMNTCGHI
134	V	S	b	0.0	1vg8_D		VIAELQTDGKFNPRS
135	A		e	49.1	1vg8_D		SVDTPAGIKLQECFNRY
136	T	H	e	42.9	1vg8_D		TSDEKIPVALFQRYMNGHW
137	K	H	e	84.9	1vg8_D		EKDSAQNRTHIPYFGLV
138	R	H	e	38.3	1vg8_D	hetero OSBL1_MOUSE	ERQKDTAILMNVFGHPSWY
139	A	H	b	0.0	1vg8_D		AGEILVDQSTMHKNPRY
140	Q	H	e	39.3	1vg8_D		QEKGRALDNHSCFIMPTVY
141	A	H	e	54.5	1vg8_D	hetero OSBL1_MOUSE	AEKQLSGDRINVHTFMPY
142	W	H	b	11.6	1vg8_D	hetero OSBL1_MOUSE	LWFYAEKVMQSGIRTCDHNP
143	C	H	b	0.0	1vg8_D		ACLFSVGRIKPTDEMNQY
144	Y	H	e	67.8	1vg8_D		AKLERYDHNSVFGIQTMPC
145	S	H	e	58.6	1vg8_D		SEDKRAQGTNVHLMP
146	K	T	b	17.9	1vg8_D		KEIRLQDHMSAGNVPTYFW
147	N	T	e	52.1	1vg8_D		GNLKEFRHDYAMQSTWCIPV
148	N	S	e	61.8	1vg8_D		GNARSDEKFIQTCHLV
149	I		b	7.0	1vg8_D		ILCVAMFTRSYKNP
150	P		e	34.1	1vg8_D		PKSALGQTCEFHIMRDVYN
151	Y	E	b	13.0	1vg8_D		FYLCHIVWAM
152	F	E	b	17.2	1vg8_D		FILYMVCHTWEGKPQS
153	E	E	b	17.1	1vg8_D		EDSAFQRGHKMNPTVY
154	T	E	b	0.0	1vg8_D		TCIVALSEGMNQ
155	S	B	b	0.0	1vg8_D	compound GTP GNP GDP	SCNAHILQT
156	A	T	b	0.9	1vg8_D	compound GTP GNP GDP	ASVCPGKLT	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"
157	K	T	e	41.0	1vg8_D	compound GTP GNP GDP	KLARTMSEFIQV	BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791" BINDING /ligand="GTP" /ligand_id="ChEBI:CHEBI:37565" ECO:0000269|PubMed:20028791"	K->N:(0.0 %):LP/P Charcot-Marie-Tooth disease, axonal, 2B (CMT2B) dbSNP:rs1219090 [MIM:600882]
158	E	T	e	57.8	1vg8_D		TEDSLNQAYKCFHIMV
159	A	T	e	48.2	1vg8_D		NGSRAQDKHMCEFL
160	I	B	e	39.2	1vg8_D		IETQLYDFHSKVMARWCNP
161	N	S	e	35.8	1vg8_D		NGSHRTCDEKLQ		N->T:(2.0 %):LP/P Charcot-Marie-Tooth disease, axonal, 2B (CMT2B) dbSNP:rs1219090 [MIM:600882]
162	V	H	b	2.0	1vg8_D		VILFTAEKMY		V->M:(1.0 %):LP/P Charcot-Marie-Tooth disease, axonal, 2B (CMT2B) dbSNP:rs1219090 [MIM:600882]
163	E	H	e	31.2	1vg8_D		EDKNQIRTYLVAFGHPS
164	Q	H	e	44.9	1vg8_D		EDKQALNRSITCGHMP
165	A	H	b	0.0	1vg8_D		AVLPISMTCDFGK
166	F	H	b	0.5	1vg8_D		FLAIKMPTVY
167	Q	H	e	57.1	1vg8_D		EQLDRTYHIKNMSFVA
168	T	H	e	20.1	1vg8_D		ETADKSWLRYCGHMNQVFI
169	I	H	b	0.0	1vg8_D		LIAVMTCF
170	A	H	b	0.9	1vg8_D		AVILTSCEFGMQR
171	R	H	e	35.6	1vg8_D		RKEQASCHLDMNT
172	N	H	e	24.2	1vg8_D		EKADNQSVHLTIRCF
173	A	H	b	0.0	1vg8_D		IAVLSHKMCFGTY
174	L	H	b	10.7	1vg8_D		LIRKVFMPESYACNQT
175	K	H	e	75.9	1vg8_D		KQRENTASGLIMPYDFHV
176	Q	H	b	19.4	1vg8_D		QRKNELDSTAHMPYGV
177	E	H	b	14.1	1vg8_D		ERKQSDPHNMFGILVYAT
178	T	H	e	33.8	1vg8_D	hetero RILP_HUMAN	TSGKRAEMNPDQCILVH
179	E	H	e	29.1	1vg8_D		ESKQRLDAGTHPIMNVY
180	V	H	e	38.7	1vg8_D	hetero RILP_HUMAN	VLIQGTDEKNPRSACFMW	MUTAGEN /note="V->A: Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments." MUTAGEN /note="V->A: Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments." DISORDER predicted by DISOPRED
181	E	H	e	41.2	1vg8_D	hetero RILP_HUMAN	EQDAHKSLNPRTVMFGI	DISORDER predicted by DISOPRED
182	L	H	e	42.7	1vg8_D	hetero RILP_HUMAN	LIAVEFKTGQRDNSYHMP	MUTAGEN /note="L->A: Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments. Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments; when associated with A- 183." MUTAGEN /note="L->A: Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments. Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments; when associated with A- 183." DISORDER predicted by DISOPRED
183	Y	H	e	29.6	1vg8_D	hetero RILP_HUMAN	FYHGLSEVAIKPRWTDNQM	MUTAGEN /note="Y->A: Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments. Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments; when associated with A- 182." MUTAGEN /note="Y->A: Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments. Does not abolish interaction with RILP and localization to late endosomal/lysosomal compartments; when associated with A- 182." DISORDER predicted by DISOPRED
184	N	H	e	76.4	1vg8_D		NGSADREQPTHIKMVCFL	DISORDER predicted by DISOPRED
185	E	H	e	61.3	1vg8_D	hetero RILP_HUMAN	EQKDGLNSAIVHRPTMY	DISORDER predicted by DISOPRED
186	F	S	e	67.9	1vg8_D	hetero RAE1_RAT	FLSADGIRKNTVQEMPY	DISORDER predicted by DISOPRED
187	P		e	59.7	1vg8_D		PGSDTKIMNAQVELR	DISORDER predicted by DISOPRED
188	E		e	56.3	1vg8_D		EDQSKLNPAGRTIVH	DISORDER predicted by DISOPRED
189	P		e	98.4	1vg8_D	hetero RAE1_RAT	PSGTDEAHQRIKNVL	DISORDER predicted by DISOPRED
190	I		e	123.4	1vg8_D	hetero RAE1_RAT	IVLGSMPTADEKQRN	DISORDER predicted by DISOPRED
191	K		e	77.8	1vg0_B	hetero RAE1_RAT	KRSDEQAGLNTHIVP	CROSSLNK /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)" CROSSLNK /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)" DISORDER predicted by DISOPRED
192	L		e	123.0	1vg0_B	hetero RAE1_RAT	LIVKPSMFREQDT	DISORDER predicted by DISOPRED
193	D	-	-	-	-		DSNEGTKRVIAPYHQ	DISORDER predicted by DISOPRED
194	K	-	-	-	-		KSLNTIPRAEFGQCDVYH	CROSSLNK /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)" CROSSLNK /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)" DISORDER predicted by DISOPRED
195	N	-	-	-	-		NGSHTKQAEPRDLIV	DISORDER predicted by DISOPRED
196	D	-	-	-	-		DNPQSTAERGLKHW	DISORDER predicted by DISOPRED
197	R	-	-	-	-		RKQESGPITLVAYDMN	DISORDER predicted by DISOPRED
198	A	-	-	-	-		ASKPGQHETVILMRN	DISORDER predicted by DISOPRED
199	K	-	-	-	-		KQRSANTEGLPDFMV	DISORDER predicted by DISOPRED
200	A	-	-	-	-		SAGTKPRNQDCEHLV	DISORDER predicted by DISOPRED
201	S	-	-	-	-		SAQTNEGKPMDLRWYCV	DISORDER predicted by DISOPRED
202	A	-	-	-	-		AGSKVEFCLPQTDIN	DISORDER predicted by DISOPRED
203	E	-	-	-	-		SGEQKADNRCFYMPTVIL	DISORDER predicted by DISOPRED
204	S	-	-	-	-		SGCKNATEHRQVP	DISORDER predicted by DISOPRED
205	C	-	-	-	-		CSAIKGTV	LIPID /note="S-geranylgeranyl cysteine" LIPID /note="S-geranylgeranyl cysteine" DISORDER predicted by DISOPRED
206	S	-	-	-	-		SGAHCENQTVYIKP	DISORDER predicted by DISOPRED
207	C	-	-	-	-		C	MOD_RES /note="Cysteine methyl ester" LIPID /note="S-geranylgeranyl cysteine" MOD_RES /note="Cysteine methyl ester" LIPID /note="S-geranylgeranyl cysteine" DISORDER predicted by DISOPRED